-+ 0.00%
-+ 0.00%
-+ 0.00%

MiNK says Phase II trial posts 77% disease control in PD-1 refractory gastroesophageal cancer

PUBT·04/17/2026 19:01:00
Listen to the news
MiNK says Phase II trial posts 77% disease control in PD-1 refractory gastroesophageal cancer
  • MiNK Therapeutics disclosed Phase II trial results for its allo-iNKT cell therapy agenT-797 in a multi-drug regimen for advanced PD-1 refractory gastroesophageal adenocarcinoma.
  • Data were presented at AACR Annual Meeting running April 17-22, 2026, with a poster session scheduled for April 20.
  • Treatment produced broad disease control, with a subset of patients showing durable survival beyond 20 months.
  • An induction approach signaled better durability outcomes than starting with full combination therapy, supporting a sequencing strategy for next-stage development.
  • Study missed primary response endpoint, shifting emphasis toward disease control and longer-term survival as decision-driving measures in this setting.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mink Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604171500PRIMZONEFULLFEED9692228) on April 17, 2026, and is solely responsible for the information contained therein.